Cara Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cara Therapeutics, Inc.
Cara Therapeutics and licensee Vifor Pharma have released positive topline data from the KALM-2 study in chronic kidney disease patients with moderate-to-severe pruritus undergoing hemodialysis, using a first-in-class selective kappa opioid receptor agonist which does not enter the CNS.
Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.
Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.
Second Phase III study expected later this year, but Cara wants to discuss the possibility of accelerated filing with the US FDA. It also has an oral formulation in Phase II for less severe CKD patients.
- Large Molecule